oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 3 )

2018 ( 4 )

2017 ( 2 )

2016 ( 11 )

Custom range...

Search Results: 1 - 10 of 2352 matches for " Rozenthal Marcia "
All listed articles are free for downloading (OA Articles)
Page 1 /2352
Display every page Item
Avalia??o neuropsicológica dos circuitos pré-frontais relacionados à tomada de decis?o na esquizofrenia: uma revis?o sistemática da literatura
Alves, Gilberto Sousa;Rozenthal, Marcia;
Revista de Psiquiatria do Rio Grande do Sul , 2006, DOI: 10.1590/S0101-81082006000300012
Abstract: objectives: a critical review of the literature was undertaken with articles assessing neuropsychological deficits in decision making (dm) in schizophrenic patients. methods: this review included all articles that performed neuropsychological assessments with tests sensitive to cortical areas associated with dm, especially the orbitofrontal cortex dysfunction. methodological aspects of the selected studies were compared, as well as the correlation between measures in dm tasks with clinical, cognitive and functional characteristics of the samples. results: eight articles between 1997 and 2005 were selected. with regard to the instrument used to assess dm, six used the iowa gambling task (igt), one used the novel decision making task (ndmt) and one used the two choice prediction task (tcpt). all the studies compared schizophrenic patients to healthy controls. in four articles using the igt and the others using either the ndmt or the tcpt, schizophrenic patients showed low performance in dm tasks. discussion and conclusion: current studies are inconclusive in assessing dm deficits in schizophrenia. clinical characteristics such as diagnostic subtype, predominant symptoms, type of medication and psychosocial functioning can account for the results found. further studies are required to better investigate the nature of dm deficits in schizophrenia and their relevance to clinical presentation and illness course.
Aspectos neuropsicológicos da depress?o
Rozenthal, Marcia;Laks, Jerson;Engelhardt, Eliasz;
Revista de Psiquiatria do Rio Grande do Sul , 2004, DOI: 10.1590/S0101-81082004000200010
Abstract: this study aims at reviewing the main neuropsychological findings in depression and the differences between the unipolar and bipolar forms, with or without psychosis, during the acute and intercritical phases. moreover, the study intends to correlate the neuropsychological findings described in the literature with neuroanatomic and neurofunctional aspects, emphasizing frontal areas and their main circuits. considering neuropsychological studies carried out in the field of affective disorders, some alterations have shown to be more consistent, with important dysfunctions in critical phases but also in asymptomatic patients. of these, attentive and mnemic aspects, in addition to executive functioning, are of special interest. studies of this nature have important therapeutical implications, suggesting the need for the development of other supporting therapeutical techniques, such as cognitive rehabilitation and psychosocial interventions, making the treatment broader and more incisive.
Avalia??o da sintomatologia depressiva de mulheres no climatério com a escala de rastreamento populacional para depress?o CES-D
Fernandes, Rita de Cássia Leite;Rozenthal, Marcia;
Revista de Psiquiatria do Rio Grande do Sul , 2008, DOI: 10.1590/S0101-81082008000400008
Abstract: introduction: the objective of this study was to evaluate depressive symptoms in climacteric women using the center for epidemiological studies depression scale (ces-d) from the national institute of mental health (usa). method: this is a cross-sectional study carried out in a gynecological outpatient unit in rio de janeiro, brazil, including 151 climacteric women between 40 and 65 years of age. the ces-d was used to assess depressive symptoms and a structured interview obtained sociodemographic, clinical and gynecological data. a score above 15 points on the ces-d was considered as a cut-point for depressive state. results: mean ces-d score was 9.2 points (standard deviation = 9.0). insomnia, sadness and despondency had the highest scores. there was no significant association between ces-d scores and the climacteric period, sociodemographic, clinical or gynecological characteristics, except for women with psychiatric symptoms, history of depression or on antidepressants (p = 0.000). in 32 women (21%) who scored > 15 on the ces-d, 72% had already suffered from a depressive state. women with no history of depressive disorder scored more frequently above 15 when they were perimenopausal. conclusion: this sample of climacteric women, from a non-specialized mental or menopausal health service, had low mean scores on the ces-d, with the item insomnia being the most highly scored. history of a previous depressive episode, but not the woman's climacteric period, was a risk factor for higher scores on the ces-d. in the group of women with no history of depression, the perimenopausal women had more scores above the cut-point. this fact may suggest that the perimenopause is a period of higher susceptibility to new onset of depressive episodes.
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
Laks Jerson,Engelhardt Eliasz,Marinho Valeska,Rozenthal Marcia
Arquivos de Neuro-Psiquiatria , 2001,
Abstract: BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD (agitation). METHOD: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.
Doen?a de Alzheimer e espectroscopia por ressonancia magnética do hipocampo
Engelhardt, Eliasz;Moreira, Denise M.;Laks, Jerson;Marinho, Valeska M.;Rozenthal, Marcia;Oliveira Jr, Amarino C.;
Arquivos de Neuro-Psiquiatria , 2001, DOI: 10.1590/S0004-282X2001000600006
Abstract: objective: acquisition of data of magnetic resonance metabolite spectrum of the hippocampal formation (hippocampus-hc) in the elderly, normal and with alzheimer's disease (ad). method: subjects matched for age: a. normal sample (n=20), cdr=0, and b. ad sample (n=40), cdr 1 and 2. technique: signa horizon lx-ge, 1.5t, 1h-mrs with automated software probe/sv, voi: hc (right and left); single voxel (2x2x2cm); tr 1500ms/te 50ms; press; metabolites: n-acetylaspartate (naa), choline (cho), creatine (cr), myo-inositol (mi). results: the present data relate to the ratios of naa, cho and mi, with cr taken as reference, and the mi/naa ratio. the study showed reduction of naa, increase of mi and of the mi/naa ratio, and not consistent results for cho. the results of the whole sample of ad patients compared to the pooled normal mean ± sd were significant for naa, mi and mi/naa (p<0.01). accuracy in relation to the individual values of both samples showed satisfactory levels of sensitivity, specificity and positive predictive value. conclusion: the present results can be used as a helpful tool to detect pathologic changes of the hippocampus in ad, and allowing greater accuracy and an earlier diagnosis of this disease.
Estudo-piloto com clozapina em hospital público: resultados de um ano de acompanhamento
Silva, Carlos Eduardo da Rocha e;Pereira, Basilio de B;Rozenthal, Marcia;Elkis, Helio;
Revista Brasileira de Psiquiatria , 2001, DOI: 10.1590/S1516-44462001000400004
Abstract: objective: a prospective study was carried out to assess the effectiveness and safety of clozapine in chronic treatment resistant schizophrenic patients followed up over one year in a public psychiatric hospital, instituto municipal nise da silveira, rio de janeiro, brazil. method: nine patients (7 men and 2 women) with diagnosis of schizophrenia (cid-10), mean age 32.8 years old (range 23 to 49 years old) and a mean duration of the illness 11.3 years (range 3 to 29 years) were under continuous clozapine treatment for a year. treatment effectiveness was assessed applying the positive, negative and general psychopathology scale (panss) and the brief psychiatric rating scale (bprs) at admission and 3, 6, 9 and 12 months. results were analyzed using paired t-test. results: by the 12th month the positive, negative and general psychopathology scale (panss) showed a statistically significant reduction. the values of panss factors (positive, negative, excitement, anxiety/depression and cognitive) were also analyzed, and it was found that only the cognitive factor showed no significant improvement. the total score on the bprs showed a significant reduction by the 12th month. no adverse events were observed during the period of the treatment. conclusions: the results suggest that clozapine, when used in public psychiatric hospitals' psychosocial rehabilitation programs, with adequate blood monitoring, is a safe and effective antipsychotic drug and should be part of the therapeutic armamentarium for chronic refractory patients. long-term observational studies with large sample sizes on clozapine or other new antipsychotic drug effectiveness are necessary to better establish these drugs' benefits in treatment-resistant schizophrenics.
Estudo-piloto com clozapina em hospital público: resultados de um ano de acompanhamento
Silva Carlos Eduardo da Rocha e,Pereira Basilio de B,Rozenthal Marcia,Elkis Helio
Revista Brasileira de Psiquiatria , 2001,
Abstract: OBJETIVOS: Estudo-piloto prospectivo e naturalístico para avalia o da efetividade e seguran a do uso da clozapina em pacientes esquizofrênicos cr nicos resistentes, em tratamento num hospital psiquiátrico público -- Instituto Municipal Nise da Silveira, localizado no Rio de Janeiro, RJ. MéTODO: Foram tratados com clozapina, por um período de um ano, monitorados com hemogramas semanais nas 18 primeiras semanas e mensais nas subseqüentes, nove pacientes (sete homens e duas mulheres) com média de idade de 32,8 (varia o entre 23 e 49) anos e dura o média da doen a de 11,3 (varia o entre 3 e 29) anos, com diagnóstico de esquizofrenia (CID-10). Os pacientes foram avaliados pela PANSS e BPRS na admiss o, no terceiro, no sexto, no nono e no 12o mês de tratamento. Os resultados foram analisados estatisticamente pelo teste t. RESULTADOS: Ao final do primeiro ano, houve redu o significativa dos valores dos sintomas positivos, negativos e de psicopatologia geral (PANSS). Quando da análise dos cinco componentes principais da PANSS (positivo, negativo, excita o, ansiedade/depress o, cognitivo), apenas o cognitivo n o apresentou redu o estatisticamente significativa. O escore total médio da BPRS apresentou diminui o significante após um ano. N o foram observados efeitos adversos importantes. CONCLUS ES: Esses resultados sugerem que a clozapina, usada em programas de reabilita o psicossocial de hospitais públicos com um adequado monitoramento hematológico, é um antipsicótico seguro e efetivo, devendo ser incluída no arsenal terapêutico dos pacientes esquizofrênicos cr nicos resistentes. Estudos controlados com tempo de seguimento longo e amostras maiores s o necessários para determinar os benefícios da clozapina e demais novos antipsicóticos em pacientes esquizofrênicos resistentes.
Cria??o, afeta??o e paradoxo em psicanálise
Rozenthal, Eduardo;
ágora: Estudos em Teoria Psicanalítica , 2009, DOI: 10.1590/S1516-14982009000100009
Abstract: the aim of the article is to outline a theoretical understanding of a current compulsive subject analysis. the contemporary subjectivities suffer of self-creation problems, beyond the dynamic of the representations, between the repressed and the symptom. the compulsion is a failure pulsional inscription try and only the transferencial affection paradox - at the same time, to affect and to be affected - would contribute to lust (jouissance) deviation. beyond the interpretation of what the analysand doesn't say, what is at stake is the possibility of the reception that could never be said, but only felt.
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
Laks, Jerson;Engelhardt, Eliasz;Marinho, Valeska;Rozenthal, Marcia;Souza, Fernando de Castro e;Bacaltchuk, Josué;Stoppe Jr., Alberto;Ferreira, R.C.R.;Bottino, Cassio;Scalco, M?nica;
Arquivos de Neuro-Psiquiatria , 2001, DOI: 10.1590/S0004-282X2001000600005
Abstract: background: behavioral and psychological symptoms in dementia (bpsd) contribute to caregiver burden and institutionalization of elderly. neuroleptics are prescribed to control agitation. side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. objectives: to evaluate efficacy and tolerability of risperidone oral solution (ros) given once daily to demented elderly outpatients with bpsd (agitation). method: patients (n=26), 76.35±8.63 years, diagnostic and statistical manual of mental disorders 4th ed. (dsm-iv) criteria for dementia. rso was given, starting dose of 0.25 mg and increments of 0.25 mg every week. mini-mental state examination (mmse) assessed cognitive status, behavioral and emotional activities manifested in dementia (beam-d) and clinical global impression (cgi) measured bpsd, extrapiramidal symptom rating scale (esrs) evaluated extrapyramidal symptoms. cardiovascular side effects were evaluated clinically. results: there was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. side effects were more prevalent above 2.5 mg. conclusion: risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. a single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.
First Note on the Definition of S2-Convexity  [PDF]
Pinheiro Marcia
Advances in Pure Mathematics (APM) , 2011, DOI: 10.4236/apm.2011.11001
Abstract: In this short, but fundamental, note, we start progressing towards a mathematically sound definition of the real functional classes 2sK
Page 1 /2352
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.